Information Provided By:
Fly News Breaks for January 9, 2020
AERI
Jan 9, 2020 | 07:04 EDT
SunTrust analyst Gregory Fraser initiated coverage of Aerie Pharmaceuticals with a Buy rating and $32 price target. In a research note to investors, Fraser says that with valuation and expectations reset, he expects the stock to appreciate as Aerie drives share growth for its glaucoma franchise in 2020 and beyond. He adds that the company has a number of intriguing pipeline opportunities that are not factored into his valuation and says the business could also be of interest to larger players looking to expand within ophthalmology.
News For AERI From the Last 2 Days
There are no results for your query AERI